Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

Author： Laird A Douglas   Cherrington Julie M  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.1, 2003-01, pp. : 51-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Advancements in Small Molecule Inhibitors of Insulin–like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 5, 2013-04 ,pp. : 653-681

Bentham Science Publishers

Access to resources Recommend Favorite

Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

By Bridges A.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 279-292

Informa Healthcare

Access to resources Recommend Favorite

Development for Anticancer Therapy: Small-Molecule Inhibitors Targeting Protein Kinase B

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 9, 2013-01 ,pp. : 1272-1294

Bentham Science Publishers

Access to resources Recommend Favorite

Protein tyrosine kinase inhibitors as anticancer agents

By Supuran Claudiu T   Scozzafava Andrea  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 1, 2004-01 ,pp. : 35-53

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule FLT3 Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1183-1193

Bentham Science Publishers

Access to resources Recommend Favorite